SCHEMBL5214847

SCHEMBL5214847

CNCCC(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
MAPK1 P28482 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
LMNA P02545 2/20 0.51
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
KMT2A Q03164 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
LTA4H P09960 2/20 0.48
MEN1 O00255 2/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HPGD P15428 1/20 0.46
ATM Q13315 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
HRH4 Q9H3N8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5214845 0.98 ALDH1A1 (0.56) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL17787475 0.90 LTA4H (0.56) ALDH1A1MAPK1L3MBTL1LMNAHTT
Hydrochloric Acid SCHEMBL25244621 0.89 LTA4H (0.54) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL20369404 0.87 EPHX2 (0.56) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL13323438 0.86 ALDH1A1 (0.61) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL8058784 0.85 ALDH1A1 (0.49) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL23901605 0.83 ALDH1A1 (0.54) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL13381210 0.83 ALDH1A1 (0.54) ALDH1A1MAPK1L3MBTL1LMNAHTT
Methylamine SCHEMBL27778913 0.83 ALDH1A1 (0.54) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL24526798 0.83 ALDH1A1 (0.56) ALDH1A1MAPK1L3MBTL1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197387-A1 BCL-XL DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-19 US disclosed
EP-4401729-A1 BCL-XL DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-24 EP disclosed
US-20230303618-A1 TRIPTOLIDE CONJUGATES AND USES THEREOF REYOUNG CORPORATION (US) 2023-09-28 US disclosed
WO-2023044046-A1 BCL-XL DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-23 WO disclosed
CN-115551841-A Azetidin-3-ylcarbinol derivatives as modulators of the CCR6 receptor 爱杜西亚药品有限公司 2022-12-30 CN disclosed
WO-2022129047-A2 NOVEL MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2022-06-23 WO disclosed
US-20180179242-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS NOVOMER, INC. 2018-06-28 US disclosed
US-9951096-B2 Catalysts and methods for polymer synthesis SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) 2018-04-24 US disclosed
EP-2966108-A2 Catalysts and methods for polymer synthesis Novomer, Inc. (US) 2016-01-13 EP disclosed
EP-2321364-B1 METHODS FOR POLYMER SYNTHESIS NOVOMER INC (US) 2015-08-12 EP disclosed
US-8119631-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-21 US disclosed
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-20100178710-A1 Mass Labels ELECTROPHORETICS LIMITED (GB) 2010-07-15 US disclosed
WO-2010022388-A2 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS NOVOMER, INC. (US) 2010-02-25 WO disclosed
EP-1322596-B1 ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2007-08-15 EP disclosed
EP-1322596-A1 ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2003-07-02 EP disclosed
US-6479518-B2 PSYCHOLOGICAL DISORDERS MERCK & CO., INC. 2002-11-12 US disclosed
US-20020042431-A1 Zwitterionic tachykinin receptor antagonists MERCK & CO., INC. 2002-04-11 US disclosed
WO-2002024629-A1 ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2002-03-28 WO disclosed
US-5719144-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042431-A1 Zwitterionic tachykinin receptor antagonists NPY5R, NPY1R, NPY2R ALDH1A1 3769/4885MAPK1 1015/4885L3MBTL1 3436/4885
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B ALDH1A1 422/4885MAPK1 2371/4885L3MBTL1 2087/4885
US-20100178710-A1 Mass Labels B2M, SRRM2, CCNB1 ALDH1A1 3091/4885MAPK1 3372/4885L3MBTL1 119/4885
US-20250197387-A1 BCL-XL DEGRADERS AND USES THEREOF XIAP, BCL2L1, BCL2L10 ALDH1A1 4101/4885MAPK1 3541/4885L3MBTL1 472/4885
US-20180179242-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS PPOX, COASY, SOD1 ALDH1A1 2255/4885MAPK1 4309/4885L3MBTL1 4790/4885
US-20230303618-A1 TRIPTOLIDE CONJUGATES AND USES THEREOF TLR9, XIAP, ENPP2 ALDH1A1 826/4885MAPK1 4505/4885L3MBTL1 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.